ANGLE’s Parsortix Enhances Melanoma Mutation Detection

ANGLE plc (GB:AGL) has released an update.

ANGLE plc, a leader in liquid biopsy technology, has announced findings from an independent melanoma study that shows its Parsortix system can isolate circulating tumor cells (CTCs) that reveal a broader range of clinically relevant DNA mutations compared to circulating tumor DNA (ctDNA) alone. These results suggest that the Parsortix system could enhance personalized treatment plans for cancer patients by providing additional genomic information. The study highlights the potential for a multi-analyte approach to refine personalized medicine in cancer care.

For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.